AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

Publikation

AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

Wissenschaftlicher Artikel/Review - 06.01.2022

Notter Julia, Seiffert Salome N, Zimmermann-Kogadeeva Maria, Bösch Anja, Wenger Robert, Strahm Carol, Frischknecht Manuel, Livermore David M, Babouee Flury Baharak

Zitation

Notter J, Seiffert S, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore D, Babouee Flury B. AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC Infect Dis 2022; 22:33.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMC Infect Dis 2022; 22

Veröffentlichungsdatum

06.01.2022

eISSN (Online)

1471-2334

Seiten

Kurzbeschreibung/Zielsetzung

Data on antimicrobial resistance mechanisms are scanty for Cedecea spp., with very variable antibiotic resistance patterns documented. Here we report the first in vivo resistance evolution of a C. davisae clinical isolate in a patient with a complex hand trauma and provide insight in the resistance mechanism, leading to therapeutic implications for this pathogen.